Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
Go back to Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults| (NASDAQ: OSMT) | Delayed: 1.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.11 | 52 Week High | $ | |||
| Open | $1.11 | 52 Week Low | $ | |||
| Day High | $1.11 | P/E | N/A | |||
| Day Low | $1.11 | EPS | $ | |||
| Volume | 3,485 | |||||

